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Abstract
A 44-year-old man is presented here with 14 years of chronic purulent sinusitis, a chronic fungal rash of the scrotum, and
chronic pelvic pain. Treatment with antifungal therapy resulted in symptom improvement, however he was unable to
establish an effective long-term treatment regimen, resulting in debilitating symptoms. He had undergone extensive work-
up without identifying a clear underlying etiology, although Candida species were cultured from the prostatic fluid. 100
genes involved in the cellular immune response were sequenced and a missense mutation was identified in the Ras-binding
domain of PI3Kc. PI3Kc is a crucial signaling element in leukotaxis and other leukocyte functions. We hypothesize that his
mutation led to his chronic infections and pelvic pain.
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Introduction and Materials and Methods
Case Report
A 44 year-old male presented with 14 years of chronic infections
and pelvic pain. Although subject to frequent respiratory and
gastrointestinal infections since childhood, his pelvic pain began at
age 30. Following initiation of antibiotic and corticosteroid
treatment for acute sinusitis, he developed a painful erythematous
scrotal rash. His core symptoms are presented in Table S1. He
initially attempted treatment with antifungals with mild improve-
ment, but his rash gradually worsened over time. After another
course of antibiotics for acute sinusitis, his rash spread to the glans
penis and he subsequently developed severe urethral, testicular,
and pelvic pain. He also began having chronic purulent sinusitis,
and since that time he has struggled to control his upper
respiratory symptoms, pelvic pain, and scrotal rash. The dynamics
of his symptoms over time is presented in Figure 1.
He has undergone treatment with numerous immunologic and
antifungal therapies including G-CSF, IFN-gamma, GM-CSF,
IVIG, IL-2, fluconazole, amphotericin B, micafungin, itracona-
zole, caspofungin, voriconazole, with varying levels of success
(Figures 2–8). He experienced substantial improvement of his
pelvic pain and skin lesions and mild improvement of his upper
respiratory symptoms with micafungin but had to forego therapy
for financial reasons (Figure 1 and Figure 5). Other regimens
including GM-CSF (Figure 3) with fluconazole and amphotericin
(Figure 2) with caspofungin (Figure 4) have also helped control
symptoms, but to a lesser degree. He has consistently noted
worsening of his pelvic pain, rash, and upper respiratory symptoms
with antibiotic treatments. Unfortunately, medication costs and
side effects have prohibited the establishment of a successful long-
term regimen. His pelvic pain and the fatigue associated with his
symptoms have significantly impacted his quality of life. His pelvic
pain limits his ability to sit for long periods of time, and his sinusitis
is associated with pharyngitis, headaches, fatigue, and malaise.
These symptoms have limited his ability to work, exercise,
maintain a social life, and enjoy dating or sexual activity.
He has undergone extensive work-up, which has failed to
identify a unifying underlying diagnosis (Tables 1, 2, and 3 and
Tables S2, S3, S4). Prostatic fluid and ejaculate cultures, however,
have grown multiple Candida species (Table 4), and immunologic
testing has demonstrated anergy to Candida antigen (Table S3).
We hypothesized that defects in the cellular immune response
may underlie his clinical condition, as we have demonstrated
previously in other chronic fungal infections. [1,2] The current
study was approved by the Institutional Review Boards of
Children’s Hospital Boston, Beth Israel Deaconess Medical Center
in Boston and Radboud University in Nijmegen, the Netherlands.
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The individual in this manuscript has given written informed
consent to publish these case details, as outlined in the PLoS
consent form available at: http://www.plosone.org/static/
plos_consent_form.pdf.’’
Results
A panel of 100 genes known to induce or modulate the immune
response was sequenced, [1] revealing a heterozygous mutation in
the gene PIK3CG, corresponding to a Val282Ala amino acid
substitution in the phosphatidylinositol-3-kinase gamma (PI3Kc)
protein (Tables 5 and 6, Figures 9 and 10). The brother and the
father of the patient tested negative for this mutation in PIK3CG,
suggestive of a de novo mutation. Unfortunately, this could not be
definitively confirmed by the DNA analysis of the patient’s
mother, as she was deceased (Table 7). The mutation is not a
known polymorphism, based on its absence in 100 in-house exome
datasets from individuals of European ancestry, and from 179
individuals sequenced as part of the 1000 genomes project. [3]
Based on a Grantham score of 64, this mutation is predicted to be
poorly tolerated for maintaining protein conformation.
Discussion
We present a patient with chronic infections and pelvic pain,
found to have a novel missense mutation in PI3Kc: a signaling
Figure 1. Dynamics of Symptoms over Time. Rash and sinusitis symptom severity presented on a scale of 0 to 10, with 10 being worst. NIH-CPSI
scores presented on the respective scales: NIH-CPSI Pain Domain: 0–21, NIH-CPSI Voiding Domain: 0–10, NIH-CPSI Quality of Life Impact Domain: 0–12
and Total NIH-CPSI Score: 0–43 (from Litwin MS, McNaughton-Collins M, Fowler FJ Jr, Nickel JC, Calhoun EA, et. al. (1999) The National Institutes of
Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research
Network. J Urol 162:369-75.
doi:10.1371/journal.pone.0068118.g001
Figure 2. Liposomal Amphotericin B (AmBisome) Treatment Schedule.
doi:10.1371/journal.pone.0068118.g002
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Figure 3. GM-CSF Treatment Schedule.
doi:10.1371/journal.pone.0068118.g003
Figure 4. Caspofungin Treatment Schedule.
doi:10.1371/journal.pone.0068118.g004
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Figure 5. Micafungin Treatment Schedule.
doi:10.1371/journal.pone.0068118.g005
Figure 6. Posaconazole Treatment Schedule.
doi:10.1371/journal.pone.0068118.g006
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Figure 7. Voriconazole Treatment Schedule.
doi:10.1371/journal.pone.0068118.g007
Figure 8. IVIG Treatment Schedule.
doi:10.1371/journal.pone.0068118.g008
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Table 1. WBC, Flow Cytometry (CD4/CD8) Cell, and NK Cell Profile.
Test March 1999 May 2000 September 2000 Units Reference Range
WBC 6.9 27.7 5.7 K/cumm 4.5–11
RBC 4.75 4.63 5.05 M/cumm 4.30–5.90
HGB 15.3 14.4 15.9 g/dL 13.9–18.0
HCT 46.2 41.3 44 % 39–55
PLT 179 189 178 K/cumm 130–400
NEU 66.1 89 60 % 45.7–75.1
LYM 18.6 7 25.3 % 14.6–41
MONO 10.8 4 6.2 % 4–12.4
EOS 4.1 1 8 % 0–5.6
BASO 0.4 0 0.5 % 0–1.2
NEU 4.6 24.6 3.4 # 1.5–8.5
LYM 1.3 1.8 # 1–4.8
MONO 0.7 1.1 # 0.2–0.8
EOS 0.3 0.2 # 0–0.7
BASO 0 0 # 0–0.2
Flow Cytometry
TOTAL WBC 6900 27700 5700 /cumm 3800–10800
LYMPH % 93 3 25.3 % 10–40
LYMPH ABS # 850 831 1442 /cumm 1200–3700
CD3% 77 71 74.2 % 60–84
CD3 ABS # 658 590 1070 /cumm 670–2450
CD4% 52 43 43.2 % 32–57
CD4 ABS # 439 357 623 /cumm 400–1500
CD8% 23 23 25.9 % 14–35
CD8 ABS # 192 191 373 /cumm 140–950
CD4:CD8 RATIO 2.26 1.87 1.668 ratio 0.80–3.20
Natural killer function 5 N/A N/A LU 20–250
CD 16/56% N/A N/A 11.1 % 3.2–23.7
CD 16/56 ABS N/A N/A 160 CELLS/UL 45–523
doi:10.1371/journal.pone.0068118.t001
Table 2. STD and Hepatitis Panel Results.
Test Sample 1999 2008 Reference
RPR Serum Nonreactive N/A Nonreactive
HBsAg Serum Negative N/A Negative
HBsAb Serum Negative N/A Negative
HBcAb Serum Negative N/A Negative
HCV AB Serum Negative N/A Negative
HIV I & II
antibodies
Serum Negative Negative Negative
Chlamydia
trachomatis
Urine Negative Negative Negative
Neisseria
gonorrhoeae
Urine Negative Negative Negative
doi:10.1371/journal.pone.0068118.t002
Table 3. Imaging Test and Special Test/Procedure Results.
Test/Procedure Date Result
Imaging Tests
CT chest 2008 Minimal lung scarring,
previous spinal surgery
CT pelvis 2008 Prostate not enlarged
(3.862.6 cm), no
calcifications
Surgeries
Cystoscopy Declined N/A
Bilateral endoscopic and laser
frontomaxiloethmoidsphenoidectomies,
septoplasty and submucous resection
of turbinates
1998 Diagnosis: Severe
obstructive
rhinosinusitis with
deviated nasal septum
and hypertrophic
turbinates
Procedures
Cystoscopy Declined N/A
doi:10.1371/journal.pone.0068118.t003
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molecule involved in a wide variety of cellular functions, including
leukotaxis. There are currently no descriptions of PIK3GC
germline mutations in humans with associated clinical phenotypes.
We hypothesize that the patient’s mutation is responsible both for
his predisposition to chronic infections and his chronic pelvic pain.
Chronic pelvic pain syndrome (CPPS) is defined as greater than
three months of pelvic pain over a six month period with no
established etiology based on routine testing. [4] Pain symptoms
can occur in the perineum, lower abdomen, testicles, penis, and
with ejaculation, and patients can also experience voiding
dysfunction. CPPS has been estimated to account for nearly two
million annual physician visits, [5] and its impact on quality of life
is similar to or greater than angina, congestive heart failure,
Crohn’s disease, and diabetes mellitus. [6] While the etiology and
pathophysiology are not well understood, many experts favor a
model of CPPS as a heterogeneous condition, with multiple
potentially overlapping etiologies existing along a spectrum. This
patient’s history may suggest a chronic fungal infection, or
potentially an autoimmune process precipitated by an inciting
fungal infection, as the cause of his CPPS. While infectious and
autoimmune mechanisms have been proposed in CPPS, they have
never been proven responsible in specific cases. Furthermore,
while multiple levels of evidence support a genetic underpinning in
CPPS, a specific mutation has never been proven responsible.
Recent evidence from the Northwestern University Prostatitis
Research group implicates mast cells in the pathogenesis of CPPS.
[7,8] Activation may result in the release of vasoactive and
inflammatory molecules in response to unknown triggers. [9] This
activation is known to be significantly dependent on PI3K-c. [10].
Despite a wide range of roles in cells throughout the body,
PI3Kc has largely been studied for its importance within the
immune system, where it participates in leukotaxis and other
elements of the immune response. Class I PI3Ks are heterodimers
consisting of a catalytic and a regulatory subunit that is further
grouped into Class IA and IB, each with respective isoforms. Class
IA PI3Ks are activated by receptor tyrosine kinases (RTKs),
whereas class IB is activated through G protein coupled receptors
(GPCR). [11,12] PI3Kc consists of a catalytic subunit, p110c, and
Table 4. Fungal Culture and Sensitivity Testing Results (Prostatic Fluid and Ejaculate).
Isolate Candida albicans Candida glabrata Periconia species
Source Prostatic secretions Ejaculate Ejaculate
Date January 2000 March 2002 August 2003
MIC, mcg/mL @ 24 hrs 48 hrs 24 hrs 48 hrs 24 hrs 48 hrs
Amphotericin B 0.125 0.25 0.06 0.25 0.5 0.5
5-FC N/A N/A 2 4 N/A N/A
Ketoconazole N/A N/A 0.125 0.125 N/A N/A
Fluconazole 0.25 0.25 4 4 16 32
Itraconazole ,=0.015 ,= 0.015 0.125 0.125 N/A N/A
Voriconazole N/A N/A ,= 0.125 ,= 0.125 0.5 1
Posaconazole ,=0.015 ,= 0.015 0.06 0.06 N/A N/A
Caspofungin N/A N/A ,= 0.125 ,= 0.125 8 8
doi:10.1371/journal.pone.0068118.t004
Table 5. Coverage Statistics of the Exome Sequencing
Procedure of the Patient.
SMB
Total mapped 21112862
On target* 72.34%
Near target** 25.26%
Off target*** 2.40%
Average target coverage 30.03
*On target: mapping to bases included in the array design
**Near target: In 500 basepair (approximate fragment length) proximity of array
targets
***Off target: Mapping to other genomic positions in the genome
doi:10.1371/journal.pone.0068118.t005
Table 6. Summary of All Genetic Variants Detected in the
Patient.
CMC-SMB
Total variants 895
of those SNVs 794
of those indels 101
Known SNPs (dbSNP 130) 827
In-house variants 91
Novel variants 57
of those coding (non-synonymous) 7
of those minimal 20% variant reads 1
doi:10.1371/journal.pone.0068118.t006
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Figure 9. Coverage of the PI3KCG Gene Specifically.
doi:10.1371/journal.pone.0068118.g009
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regulatory subunits, p101 or p84/p87. [13] Upon binding of
chemokines or other ligands to GPCRs, PI3Kc is activated
through binding to the bc subunit of a heterotrimeric G-protein.
PI3Kc activation is also enhanced by binding of the GTPase Ras
to the Ras-binding domain of p110c, which lies directly adjacent
to the catalytic domain. [13] This initiates the signaling cascade
that results in chemotaxis in multiple leukocyte lineages, both
within the adaptive and innate immune responses. In addition, it
activates other leukocyte functions, including the oxidative burst in
neutrophils. [14] In vivo models have demonstrated decreased
inflammation and susceptibility to infections when PI3Kc function
is abrogated, making it an attractive target in the treatment of
inflammatory, allergic and autoimmune diseases. [14,15].
Beer-Hammer and colleagues demonstrated that p110c con-
tributes to T and B cell development, and is variably expressed
throughout the hematopoietic process. [16] The c catalytic subunit
plays a very different role from other IB class members, directly
interacting with the G-protein bc dimers and Ras proteins. Several
studies have looked at p110c/p110d mutants p110c-deficient
animals, homozygous for a KD p110d mutant, show profound T
cell lymphopenia accompanied by multiple organ inflamma-
tion,[15,17–19] while mutations only in p110c primarily causes
defects in neutrophil and mast cell function. [19] These mutations
have shown specificity in affecting TCR-induced T cell activation.
[18] PI3Kc has been implicated in leukocyte migration, regulation
of T-cell proliferation and cytokine release, [10] and most recently
mast cell activation. [20] Overexpression of p110c was shown to
induce oncogenic transformation of chicken embryo fibroblasts, if
Ras binding occurred. [21] P110c overexpression has also been
documented in chronic myeloid leukemia, [22] presenting it as an
potential oncogene through the recent literature.
The Val282Ala mutation occurs within the Ras-binding domain
of the p110c subunit of PI3Kc. Functional studies will be
necessary to determine the specific effect of the Val282Ala
mutation on the activity of PI3Kc, but one can hypothesize that
decreased activity could suppress the immune response by
inhibiting leukocyte migration and function. This could explain
the patient’s history of frequent and chronic infections. Addition-
ally, it could potentially explain his chronic pelvic pain, through
several different mechanisms. The history suggests that the
patient’s cutaneous fungal infection likely spread to the urinary
tract after extending to the glans penis, and may have subsequently
involved the urethra, epididymis, testicles, prostate, or other areas
within the genitourinary system. With failure to completely
eradicate the infection due to impaired leukocyte activity, chronic
infection alone may have caused his pain symptoms. Another
possibility is that the initial infection within the genitourinary
system may have been effectively treated by antifungal therapy but
subsequently incited an autoimmune process, which can result
from infection via multiple mechanisms. [23] Alternatively, a
mutation in PI3KCG that resulted in over-activation could cause
inflammation through an autoimmune mechanism, resulting in
chronic pelvic pain. Further studies will be necessary to determine
the activity of the mutant protein and elucidate the exact
mechanisms of injury.
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Figure 10. Validation of Mutation by Sanger Sequencing.
doi:10.1371/journal.pone.0068118.g010
Table 7. Family History.
Relative Status/Description
Mother Deceased: Colon cancer. Chronic respiratory
symptoms in response to mold in the office
building where she worked. She subsequently
became very sensitive to air pollution,
tobacco smoke, and molds. Migraine
headaches that kept her in bed for days.
Alcohol caused severe headaches, which
would lead to vomiting. Two miscarriages,
two other pregnancies (patient and his
brother) uneventful
Father Alive, well, 75-years old. Hypertension.
Cataract surgery, otherwise in good health
Brother 37- years old. History of frequent ear
infections as a child. Current symptoms:
severe acne, hives, and rosacea. Ongoing
difficulties with coordination, experiences tics
in his eyebrows. Ongoing sleep difficulties,
but MRI and psychiatric examination were not
indicative of any pathological conditions. Has
difficulty keeping a job, lives with father
Maternal grandfather Deceased of stomach cancer at age 77,
otherwise healthy prior to cancer onset
Maternal grandmother Deceased at age 90
Paternal grandmother Deceased of breast cancer in her 70 s
Paternal grandfather Deceased of a heart attack in his late 60 s
doi:10.1371/journal.pone.0068118.t007
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